Trial Profile
An Open Label, Pilot Study of Dose-Dense Adriamycin [doxorubicin] Plus Cyclophosphamide (AC) Followed by ABI-007 [Abraxane, paclitaxel] as Adjuvant Therapy for Patients With Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Early breast cancer
- Focus Adverse reactions
- 19 Jul 2007 Status changed from in progress to completed.
- 24 Sep 2005 New trial record.